Home > Insider Trading > Filing (0001181431-14-002531)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1253689	Glycomimetics Inc	GLYC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219871	M David Mott	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1235112	J Patrick Kerins	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1270521	Kittu Krishna Kolluri	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1277631	Forest Baskett	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1302106	D Ryan Drant	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1362942	R Harry Weller	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1452907	New Enterprise Associates 13 Lp	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1460751	Nea 13 Gp, Ltd	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1460752	Nea Partners 13, Limited Partnership	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1479386	Ravi Viswanathan	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-01-15	3,580,877	$0.00	3,580,877	No	4	C	Direct
Common Stock	Acquisiton	2014-01-15	512,500	$8.00	4,093,377	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2014-01-15	11,824,058	$0.00	3,580,877	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

This represents shares received upon conversion of shares of Series A-1 convertible preferred stock.
Effective immediately prior to the closing of Issuer's initial public offering of its common stock, each share of Series A-1 Preferred Stock automatically converted into approximately 0.3028 shares of the Issuer's common stock. The Series A-1 Preferred stock had no expiration date.
The shares are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and each of the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 13 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Ryan D. Drant, Patrick J. Kerins, Krishna "Kittu" Kolluri, David M. Mott, Scott D. Sandell, Ravi Viswanathan and Harry R. Weller. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Indirect Reporting Persons have no pecuniary interest.